Chia Tai Tianqing Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Chia Tai Tianqing Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Chia Tai Tianqing presents a practical BD-screening case because its returned pipeline contains 233 records and the deal search returned 5 transaction records. The lead returned asset is Rovadicitinib, associated with JAK1 x JAK2 x ROCK1 x ROCK2 and Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Primary Myelofibrosis, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Rovadicitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: JAK1 x JAK2 x ROCK1 x ROCK2; Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Primary Myelofibrosis. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI | Approved asset with JAK1 x JAK2 x ROCK1 x ROCK2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Culmerciclib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: CDK2 x CDK4 x CDK6; Hormone receptor positive HER2 negative breast cancer, HER2-negative breast cancer, Hormone receptor positive HER2 positive breast cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sino biopharm unit licenses blood cancer drug to sanofi for up to $1.53 billion | Approved asset with CDK2 x CDK4 x CDK6 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Recombinant human coagulation factor VIIa (ChiaTai Tianqing) | Nanjing Shunxin Pharmaceutical Co., Ltd. | Approved | Pipeline record: factor VIIa; Hemophilia A, Hemophilia B, Postoperative Hemorrhage. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH | Approved asset with factor VIIa exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Pertuzumab biosimilar (Chia-tai Tianqing) | Nanjing Shunxin Pharmaceutical Co., Ltd. | Approved | Pipeline record: HER2; HER2 Positive Breast Cancer, Locally advanced breast cancer, early abortion. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI | Approved asset with HER2 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Garsorasib | Shanghai Chia Tai Tianqing Pharmaceutical Tech Dev Co. Ltd. | Approved | Pipeline record: KRAS G12C; KRAS G12C mutant Non-small Cell Lung Cancer, KRAS G12C mutant non-squamous non-small cell lung cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sino biopharm unit licenses blood cancer drug to sanofi for up to $1.53 billion | Approved asset with KRAS G12C exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-05-18 | 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI | Active | disclosed: false |
| 2026-03-04 | Sino biopharm unit licenses blood cancer drug to sanofi for up to $1.53 billion | Active | disclosed: false |
| 2026-01-29 | Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH | Active | total_amount: 500; disclosed: false |
The most relevant returned precedent is: 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI (2026-05-18). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- 华控康泰 - 二零二一年年报: 华控康泰 - 二零二一年年报 ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES 山西省高速公路集团有限责任公司 （「山西高速公路」） Shanxi Province Expressway Group Limited Liability Company* (“Shanxi Expressway”) 山西交通控股集团有限公司（「山西交通」） Shanxi Transportation Holdings Group Co., Ltd.* (“Shanxi Transportation”) Ltd.* (“Shanxi Transportation”) 山西省国有资本运营有限公司 （「省国资运营公司」） （前称山西省国有资本投资运营有限公司） Shanxi State-owned Capital Operation Co., Ltd.* (“State-owned Capital Operation Co.”) (Formerly known as Shanxi State Capital (Formerly known as Shanxi State Capital Investment and Operation Co., Ltd.*) Investment and Operation Co., Ltd.*) 山西省人民政府国有资产监督管理委员会 （「山西省国资委」） State-owned Assets Supervision and 受控制法团权益 Interest of a controlled corporation 3,172,778,000(9) 56.77% State-owned Assets Supervision and Administration Commission of Shan Xi Provincial
- PATH corporation - Quarterly securities report-28th Period2Quarter(2017.07.01-2017.09.30): PATH corporation - Quarterly securities report-28th Period2Quarter(2017.07.01-2017.09.30) 第一部【企业情报】 （2）キャッシュ・フローの状况 当第２四半期连结累计期间における现金及び现金同等物（以下、「资金」という。）は、前连结会计年度末に比 べ266,976千円増加し527,908千円となりました。 当第２四半期连结累计期间における各キャッシュ・フローの状况とそれらの要因は、次のとおりであります。 （営业活动によるキャッシュ・フロー） 当第２四半期连结累计期间の営业活动によるキャッシュ・フローは94,025千円の収入（前年同四半期は86,990千 円の支出）となりました。主な要因は、债务保证损失引当金の减少8,802千円、たな卸资产の减少84,378千円、本 社移転损失引当金の减少31,580千円及び税金等调整前四半期纯利益が6,265千円発生したことによるものです。 （投资活动によるキャッシュ・フロー） 当第２四半期连结累计期间の投资活动によるキャッシュ・フローは6,291千円の支出（前年同四半期は95,091千 円の支出）となりました。主な要因は、无形固定资产の取得による支出2,091千円及び敷金及び保证金の差入によ る支出4,200千円によるものです。 （财务活动によるキャッシュ・フロー） 当第２四半期连结累计期间の财务活动によるキャッシュ・フローは179,242千円の収入（前年同四半期は108,993 千円の収入）となりました。主な要因は、株式の発行による収入によるものです。 （3）経営方针・経営戦略等
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Chia Tai Tianqing is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Chia Tai Tianqing merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Rovadicitinib, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
